EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Interferon therapy upon hbeag positive chronic hepatitis type b correlation between disappearance of hbeag and it's clinical features



Interferon therapy upon hbeag positive chronic hepatitis type b correlation between disappearance of hbeag and it's clinical features



Journal of the Iwate Medical Association 42(6): 941-956



The correlation between the disappearance of HBeAg (SN), including appearance of anti HBe (SC), and the clinical features after interferon therapy were evaluated on twenty six patients with biopsy-proved chronic hepatitis type B. All of them were initially positive for HBeAg and received interferons for 28 consecutive days. Concentration of HBeAg and anti-HBe, DNA polymerase (DNAP) activity, and 2'-5'Oligoadenylate synthetase (2-5 AS) activity were measured before, during and after the interferon therapy, consecutively. The results were as follows. 1) The gradual increase of 2-5AS activities were observed dose dependently within 7 days after the start of interferon therapy which suggests the antiviral status occurred in the patients. 2) The SN and SC rates were 28.0% and 12.0% at one year, and 69.2%, 30.8% at two years after the interferon therapy respectively. 3) SN was more commonly observed in the cases of lower HBeAg concentration (less than 100 units), lower DNAP activity (less than 500 CPM) and the high level of GPT in the serum at the start of interferon therapy. 4) SN and SC more frequently occurred in the cases of decreasing HBeAg concentration, decreasing DNA-P activity and rising GPT levels in the serum at the start of interferon therapy. 5) Cases with fluctuating GPT levels after SN or SC, normal GPT levels with continuous HBeAg or reappearance of HBeAg after SN were occasionally found.

(PDF emailed within 1 workday: $29.90)

Accession: 007476079

Download citation: RISBibTeXText



Related references

The prospective study of the clinical features and outcome of HBeAg-negative and HBeAg-positive cirrhosis in patients with chronic type B hepatitis. Zhonghua Yi Xue Za Zhi 87(26): 1832-1835, 2007

Reversion from HBeAg negative to HBeAg positive phenotype after interferon therapy for chronic hepatitis B. Hepatology 30(4 PART 2): 601A, 1999

An analysis of clinical features in HBeAg-negative and HBeAg-positive chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 15(6): 428-430, 2007

Kinetics of serum HBsAg and intrahepatic cccDNA during pegylated interferon therapy in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Journal of Medical Virology 89(1): 130-138, 2016

Precore stop mutant in HBeAg-positive patients with chronic hepatitis B: clinical characteristics and correlation with the course of HBeAg-to-anti-HBe seroconversion. Journal of Clinical Microbiology 40(1): 16-21, 2002

Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment. Antimicrobial Agents and ChemoTherapy 59(7): 4121-4128, 2016

Quantifiable changes in HBeAg expression predict therapeutic efficacy of peg-interferon alfa-2a in patients with HBeAg-positive chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 21(5): 335-339, 2014

Liver histopathological features influencing HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B responding to Peg-IFN treatment. Zhonghua Gan Zang Bing Za Zhi 21(5): 340-344, 2014

HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 47(2): 428-434, 2008

Monitoring of HBeAg levels may help to predict the outcomes of lamivudine therapy for HBeAg positive chronic hepatitis B. Journal of Viral Hepatitis 12(2): 216-221, 2005

What Should Be the Endpoints of Oral Therapy in HBeAg-positive Versus HBeAg-negative Patients with Chronic Hepatitis B. Current Hepatitis Reports 11(2): 65-69, 2012

The curative effect of adefovir dipivoxil treating HBeAg negative chronic hepatitis B and treating HBeAg positive chronic hepatitis B combining interferon α-2b. Pakistan Journal of Pharmaceutical Sciences 28(4 Suppl): 1493-1497, 2015

Predictors for early HBeAg loss during lamivudine therapy in HBeAg-positive chronic hepatitis B patients with acute exacerbation. Hepatology International 5(1): 586-596, 2010

Effect of the precore mutations on the HBeAg loss and viral breakthrough during lamivudine therapy in HBeAg-positive chronic hepatitis B. Hepatology 38(4 Suppl 1): 723A, October, 2003

A comparison of clinical and virological characteristics of 1686 cases of HBeAg-negative and HBeAg-positive chronic hepatitis B. Zhonghua Nei Ke Za Zhi 44(9): 648-651, 2005